LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values

Li,Qingyong; Li,Panrong; Su,Jinling; Liu,Suping; Yang,Xiaoman; Yang,Yuejin; Niu,Suocheng

doi:10.3892/etm.2019.7671

LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values

Authors:
- Qingyong Li
- Panrong Li
- Jinling Su
- Suping Liu
- Xiaoman Yang
- Yuejin Yang
- Suocheng Niu
View Affiliations

Affiliations: The Second Department of Cardiology, The People's Hospital of Puyang, Puyang, Henan 457000, P.R. China, Fuwai Cardiovascular Hospital, Chinese Academy of Medical Sciences, Beijing 100037, P.R. China
Published online on: June 13, 2019 https://doi.org/10.3892/etm.2019.7671
Pages: 1221-1225
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor‑κB interacting long non‑coding RNA (LncRNA NKILA) is a well‑studied tumor suppressor lncRNA in several types of malignancies. The present study reports the involvement of this lncRNA in diabetic cardiomyopathy (DC). A 8‑year‑follow‑up study on 312 diabetic patients without exhibiting obvious complications demonstrated that plasma lncRNA NKILA levels were upregulated specifically in diabetic patients who developed DC but not in patients with other complications. Plasma levels of lncRNA NKILA at 6 months prior to diagnosis is sufficient to distinguish patients with DC from other diabetic patients without significant complications. Although in vitro experiments demonstrated that lncRNA NKILA expression in cardiomyocyte cells was not affected by high‑glucose treatment, ectopic lncRNA NKILA expression and lncRNA NKILA knockdown potentiated, and inhibited cardiomyocyte apoptosis, respectively. Therefore, the data from the present study suggests that overexpression of lncRNA NKILA is involved in DC, and overexpression of lncRNA NKILA may serve as a therapeutic target for treating DC.

View Figures

View References

1	Forbes JM and Cooper ME: Mechanisms of diabetic complications. Physiol Rev. 93:137–188. 2013. View Article : Google Scholar : PubMed/NCBI
2	Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH and Karter AJ: Rates of complications and mortality in older patients with diabetes mellitus: The diabetes and aging study. JAMA Intern Med. 174:251–258. 2014. View Article : Google Scholar : PubMed/NCBI
3	Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK and Wong J: Long-term complications and mortality in young-onset diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 36:3863–3869. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fuentes-Antrás J, Picatoste B, Ramírez E, Egido J, Tuñón J and Lorenzo Ó: Targeting metabolic disturbance in the diabetic heart. Cardiovasc Diabetol. 14:172015. View Article : Google Scholar : PubMed/NCBI
5	Battiprolu PK, Lopez-Crisosto C, Wang ZV, Nemchenko A, Lavandero S and Hill JA: Diabetic cardiomyopathy and metabolic remodeling of the heart. Life Sci. 92:609–615. 2013. View Article : Google Scholar : PubMed/NCBI
6	Falcão-Pires I and Leite-Moreira AF: Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 17:325–344. 2012. View Article : Google Scholar : PubMed/NCBI
7	Huynh K, Bernardo BC, McMullen JR and Ritchie RH: Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 142:375–415. 2014. View Article : Google Scholar : PubMed/NCBI
8	Jia G, DeMarco VG and Sowers JR: Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 12:144–153. 2016. View Article : Google Scholar : PubMed/NCBI
9	Beltrami C, Angelini TG and Emanueli C: Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol. 89:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhuo C, Jiang R, Lin X and Shao M: LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 8:1429–1437. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhang M, Gu H, Chen J and Zhou X: Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopathy. Int J Cardiol. 202:753–755. 2016. View Article : Google Scholar : PubMed/NCBI
13	Bian D, Gao C, Bao K and Song G: The long non-coding RNA NKILA inhibits the invasion-metastasis cascade of malignant melanoma via the regulation of NF-κB. Am J Cancer Res. 7:28–40. 2017.PubMed/NCBI
14	Bird L: lncRNA NKILA: A killer regulator. Nat Rev Immunol. 18:666–667. 2018. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Tao F, Xu Y, Yang D, Tian B, Jia Y, Hou J and Dong M: LncRNA NKILA correlates with the malignant status and serves as a tumor-suppressive role in rectal cancer. J Cell Biochem. 119:9809–9816. 2018. View Article : Google Scholar : PubMed/NCBI
17	Ke S, Li RC, Meng FK and Fang MH: NKILA inhibits NF-κB signaling and suppresses tumor metastasis. Aging (Albany NY). 10:56–71. 2018. View Article : Google Scholar : PubMed/NCBI
18	Jia G, Whaley-Connell A and Sowers JR: diabetic cardiomyopathy: A hyperglycaemia-and insulin-resistance-induced heart disease. Diabetologia. 61:21–28. 2018. View Article : Google Scholar : PubMed/NCBI
19	Wu W, Liu X and Han L: Apoptosis of cardiomyocytes in diabetic cardiomyopathy involves overexpression of glycogen synthase kinase-3β. Biosci Rep. 39:BSR201713072019. View Article : Google Scholar : PubMed/NCBI
20	Diao X and Li G: Down-regulation of miR-30b reduces cardiomyocyte apoptosis by targeting Bcl-2 in diabetic cardiomyopathy. Int J Clin Exp Med. 10:5296–5305. 2017.
21	Pan YL, Han ZY, He SF, Yang W, Cheng J, Zhang Y and Chen ZW: miR-133b-5p contributes to hypoxic preconditioning-mediated cardioprotection by inhibiting the activation of caspase-8 and caspase-3 in cardiomyocytes. Mol Med Rep. 17:7097–7104. 2018.PubMed/NCBI
22	Shan ZX, Lin QX, Deng CY, Zhu JN, Mai LP, Liu JL, Fu YH, Liu XY, Li YX, Zhang YY, et al: miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 584:3592–3600. 2010. View Article : Google Scholar : PubMed/NCBI